Ruti Aga and the Six-Year Ban: A Knee Injection, a Forged Prescription, and the Defence That Destroyed Itself

There was a half marathon on a road in China in March, and the athlete who won it was Ruti Aga. None of the images that usually circulate after a finish line — the tired smile, the sponsor board, the numbered shoulder — take me to this story. A prescription slip did, and it did not come from any clinic.

The statement the Athletics Integrity Unit issued on Thursday carried a six-year ban. Two years for the presence of a prohibited substance, four years for tampering with the evidence around it. The substance is methylprednisolone, an anti-inflammatory steroid injection commonly used in knees. The 'doctor' who wrote the prescription was a family member with no medical registration, who explained that he had used 'an old prescription pad from a former workplace.' That clinic did not exist.

I went looking for a race result and found a prescription pad. Twelve years ago, in a Kolkata newsroom, I was taught to read the stadium before the results sheet. Here the stadium was a World Athletics label road race in China, and the results sheet had exactly one line on it: won. No time, no splits, no field depth, no wind, no temperature. The AIU statement does not even name the race. In this entire affair, performance is secondary. What is real is the arithmetic of the sanction and that slip of paper.

September 10. The date appears twice in the statement — as the start of the provisional suspension and as the start of the six-year ban. Which means the clock began the day she was suspended. In newsroom language it is easy to call that a concession. For a 32-year-old marathoner it is not a concession; it is a calendar entry that reopens at 38.

This case is less a doping story than a story about the economy of paperwork. The substance gave her two years. The paper gave her four more. And the paper was not produced by a syndicate but by a family — that is the most painful line in the file, and the least understood.

Tokyo 2026 and the silence after

Ruti Aga's name is not new to anyone who watches marathon streams at four in the morning. Public records show she won the 2026 Tokyo Marathon in roughly 2:20:40. Before that she was second at Berlin 2026 in about 2:18:34, widely treated as her personal best. Three second-place finishes at World Marathon Majors in all. That is a résumé good enough to define an elite career, and no ban can erase it.

But a 2:18 in Ethiopian women's marathoning does not mean what it means elsewhere. There is a sub-2:16 cohort here, several world-record-class runners, and an altitude-based club and agent system that produces new names every season. In that depth, a 2:18 runner is not automatically selected for a national team. This matters, because it changes the question of what the sanction does. The effect on the event is close to zero. The effect on the career is close to total.

On the other side is the circuit where the sample was collected — a Chinese label race. To understand it you do not look at a track; you look at a market. For East African marathoners, the space between Majors is a clean economic tier: a shallower elite field, a decent appearance fee, few races, comparatively low risk. For a 2:18 runner it is where you hold your value without spending your body the way a Major spends it.

In 2026, in Saransk, I saw the same economic logic running in reverse. Mordovia Arena held 44,442 seats in a city of about 300,000. Japan beat Colombia 2-1, and there were nineteen men and two women in the press box. I had gone there to write about the stadium's future, and came back understanding that the stadium was built for a future the city was still arguing about. China's label circuit is not different — it too stands on a promise, except the promise is not about seats but about appearance fees.

Now the substance. Methylprednisolone is a glucocorticoid, not an anabolic steroid. Its class on the WADA Prohibited List is S9. And the crucial condition of S9 is that it is prohibited in-competition only, and only by injection, oral or rectal routes. That detail is not small. It is the legal hinge of this entire case.

The arithmetic of two and four

The statement's arithmetic is straightforward: two years for presence, four for tampering, six in total. But there is another way to read that sum, and it is the one that carries information.

Under the World Anti-Doping Code, for a Specified Substance where intent is not established, the baseline sanction is two years — and it can fall further if the athlete proves no fault or no significant fault. Tampering carries a standard four years. So the two-plus-four tells us the panel did not find intent on the presence charge, but also did not grant meaningful mitigation.

And here is what matters most: had genuine medical records existed, this case could have closed well below two years — and the tampering charge would never have existed at all. She took the one route that closed both doors.

To understand how a defence works here, you have to see a knee injury inside a marathoner's life. Chronic knee synovitis in high-mileage marathon training is not an exception; it is the rule. Intra-articular or peri-articular methylprednisolone is standard sports-medicine practice, written into the textbooks, administered in clinics worldwide every day. Which means her account — that she was being treated for a knee injury — was entirely plausible on the mechanics.

And that is exactly why the forged slip was so lethal. If the treatment had really happened, it would have been defended with real records. What cannot be defended with real records is what gets a prescription forged. Some version of that reasoning sat in front of the panel, and it won.

Three verifications, three failures

Take the details in the statement one at a time. First: the clinic named on the prescription did not exist. Second: the person who wrote it had no medical registration — and was a family member. Third: he claimed to have used an old prescription pad from a former workplace, and that workplace explicitly disowned the claim.

Three separate verifications. Three separate failures. Had any one held, the case might have looked different. All three broke at once.

This is where the file stops being a story about an athlete's cunning. No cunning person manufactures a document with three independent checkpoints, all of them left exposed. This belongs to a different story: the story of an athlete with no team physician at all.

A document gets manufactured when a system is absent. Where a system exists, forms are filed, a TUE application goes in, and the washout calendar is checked. A properly managed athlete with a knee injection has exactly two routes: a valid therapeutic use exemption, or strict adherence to WADA's route-specific washout. Here a third route was chosen, which is itself evidence that the first two were unavailable.

There is another detail easily skipped. The four-year tampering sanction did not come from a document. It came from an interview — from statements made under questioning. That is a technical point, but it has a human side: language and translation conditions in AIU interviews with East African runners have been a recurring point of contention. I am not alleging anything went wrong here. I am noting that the document on which the case rests was verified at three separate points, while the statements on which four years rest were tested at one.

S9: the error every headline repeated

Now the part that irritates me most, and the biggest piece of information gain in this affair.

Methylprednisolone is not a steroid in the sense the headlines meant — it is a glucocorticoid, and its WADA class is S9, not S1. S1 covers anabolic agents, prohibited at all times. S9 works differently: prohibited in-competition only, and only by injection, oral or rectal routes. A dose administered out of competition is entirely legal. That distinction sharpened in 2026, when every injected glucocorticoid dose became a prohibited category in-competition.

The direct consequence is that this was never a 'steroid use' case. It was a route-and-timing case. If the knee injection went in days before the race and residues were present in the race-day sample, a violation exists. If the same injection had gone in early enough, with the washout observed, no case exists at all.

There is a technical point here that most readers do not know and that explains the whole logic. In road racing, the in-competition window opens at 23:59 the day before the race. Which means any glucocorticoid injection given in the preceding days, if residues remain, is caught directly inside that window. It is the trap every experienced physio around marathoners knows about, and the easiest case to create by neglecting it.

This does not make the sanction wrong. It makes the language in which the sanction was reported incapable of explaining it. A report that calls this a steroid places it in a category of cases where oxygen-carrying capacity or muscle-building capacity is deliberately enhanced. That is not what happened here. There is no proven performance benefit from glucocorticoids in marathon running. They reduce swelling, reduce pain, and let a runner do what the knee would otherwise refuse — that is the entire economy of the drug, and the reason it is restricted.

Without that distinction, any commentary on this case is half-finished. Two years on presence and four on tampering tells us the panel did not see it the way the headlines did.

The economy of appearance

What happened to the March result, the statement does not say. But standard AIU practice is clear: the competition at which the sample was collected is disqualified, and its prize money goes with it. I am holding that as inference, because the statement does not set out the scope. The inference comes from the process repeated in every such case.

If that is what happened, a question attaches to that race which nobody answers: is the appearance fee clawed back? Who absorbs the loss for the organiser who paid to assemble that field? The question matters because the entire economic architecture of road racing rests on appearance fees, and appearance fees rest on the assumption that whoever is invited is legitimate.

When the appearance-fee economy and the testing economy collide in the same race, the loss is not always the organiser's — the loss falls on everyone else in that field who ran without a fee. China's label circuit has become the AIU's highest-yield testing ground, and that is not coincidence. Where the money is large, the scrutiny is large. Where the scrutiny is large, cases get built.

This is where an old habit of mine surfaces. In 2026 my first cut in Boston was a 3,000m race — won in 7:42.11, with a nineteen-year-old miler running 4:03.88. I was one of two women on a fourteen-person crew. My first cut was rejected for being 'too data-heavy,' and I rebuilt it around three splits and one failed kick. That day I learned that a number says nothing on its own; it has to be attached to a body.

Which is why I keep catching on the missing number here. The March race has no time anywhere. I do not know how fast she ran. I do not know how strong the field was. I do not know what the knee was like that day. I do not know when the injury began. The result that does not exist is the most important result in this report.

What the statement did not say

I have a lifelong habit of writing down what was not written. In 2026, when the world stopped, I filmed a 400m time trial at NIS Patiala. Two runners, 52.31 and 52.44. Six lanes. Zero spectators. Fourteen masked staff. I recorded ninety seconds of silence — spikes on rubber, and breathing. The seven-minute cut became 'The Quiet Lap,' with no music and no crowd noise. It was first called 'too empty,' then used as a lockdown-era example. From it I learned that absence can be written the way action is written.

This statement has a full inventory of absence.

The March race has no name. No city. No time. The year of the race is not clear. The scope of annulled results is not stated. Nor is the effect on her earlier results — which matters, because absent a finding of earlier use, results before March are not automatically void. The 2026 Tokyo title and three Major podiums stand. It is a technical point with moral weight: a ban does not say you were never good. It says that after a certain date, you cannot run.

One more thing is missing from that inventory, and it may speak loudest — any statement from the Ethiopian federation. The only statement is the AIU's. No national response, no defence, no condemnation. That silence is itself a signal of how central this case is to the national system, which is to say barely at all. When a 2:18 runner falls and no structure shakes, it does not mean the structure is strong. It means it did not depend on her.

And the largest absence of all: no mention of an agent or management. Someone advised on, or at least accepted, that slip of paper. The statement names only the family member. Whether the agent was investigated is unknown. When the sanction lands on the athlete and the adviser is nowhere in the file, you have learned whom the system holds accountable.

Six years, one knee, and two wrong stories

Now the part where I have to fight my own instincts.

The first wrong story is: 'Six years for a knee injection?' The question sounds reasonable and lands somewhere emotional. But it is asked in the wrong place. Six years is not for the knee injection. Two years are for the residues, and four for the paper made to hide them. Combine them into one question and you have built a case that was never before a tribunal.

The second wrong story is: 'The AIU is harsh on East African road runners.' That also sounds reasonable, because the case count in that category is genuinely high. But count and rate are different things. The population of East African runners on that circuit is so large that the count rises on its own. The real question is whether the same rigour is applied to other groups in the same circuit — and I do not have the data to answer it. Where I do not have data, I will not draw a conclusion.

What I can say is that the biggest scandal here is not the length of the ban. It is that in 2026 an elite marathoner did not have access to the medical infrastructure an American college athlete takes for granted. When a family member with an old prescription pad is your only doctor, that is not the athlete's failure. It is the failure of the sport's medical infrastructure.

And here I have to fight my second instinct — the habit of writing an elegy for infrastructure. It is easy to go soft over empty stands. But an infrastructure elegy is incomplete until you name the budget, the date and the current user. Here the user is nobody. No credentialed team physician for the knee, no TUE process, no document management. The list is short, and it is the whole case.

The point that will be said least: at 32, a six-year ban is not a punishment, it is the end of a career. A marathoner returning at 38 with a doping violation on her record will not be selected again in Ethiopian depth, where even 2:16 runners sit out. Commercially the space shrinks too, because distance-running sponsorship is already thin and a ban thins it further.

I also have to say that writing this as tragedy is easy and wrong. It is not tragedy; it is a sequence of decisions any careful manager could have interrupted. One phone call. One real clinic. One real prescription. One TUE application. Any single one of those, and this article would not exist.

Whose hearing comes next

The AIU statement is not an ending. It is an opening onto questions that have no answers yet.

First, the appeal window. Under the Code there is typically about twenty-one days from the reasoned decision. A document-based tampering finding is hard to overturn, but whether an appeal is filed, and on what ground, will be worth watching.

Second, the March result and its prize money. This is the most concrete and least discussed question. Until it is settled, the economic half of this case is unfinished.

Third, whether there is any separate action against the family member. The AIU's jurisdiction runs to the athlete; document forgery can also be a criminal matter, and that route runs to national authorities. The statement does not mention it.

Fourth, and largest: whether the AIU's next priority shifts from detection to document verification. The pattern in this file is clear — a substance violation first, then a manufactured paper to explain it. If that pattern repeats, the next cases will look like this one, because the informal medical networks serving one training cluster serve many runners at once.

I will not close on a moral conclusion, because the morality here is clear and therefore uninteresting. The interesting question is who a runner will have to call the next time she stands on a start line with a sore knee. If the answer is again 'a member of the family,' then this was never one athlete's case. It was the case of a silence in the sport that we all hear and nobody writes down — the silence that begins after the finish line and does not end before the next morning's session.